(NASDAQ: OCS) Oculis Holding Ag's forecast annual revenue growth rate of 322.47% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 86.2%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.83%.
Oculis Holding Ag's revenue in 2025 is $622,222.On average, 4 Wall Street analysts forecast OCS's revenue for 2025 to be $50,363,855, with the lowest OCS revenue forecast at $20,100,873, and the highest OCS revenue forecast at $64,211,123. On average, 4 Wall Street analysts forecast OCS's revenue for 2026 to be $1,072,716,602, with the lowest OCS revenue forecast at $40,201,746, and the highest OCS revenue forecast at $2,801,280,029.
In 2027, OCS is forecast to generate $2,829,477,087 in revenue, with the lowest revenue forecast at $2,646,056,619 and the highest revenue forecast at $3,012,897,556.